KYORIN Pharmaceutical Co., Ltd. (KYORIN PHARMACEUTICAL CO LTD) aktie

KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, and Uritos KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; and prescription medicines and quasi-drugs, and diagnostics business. In addition, the company offers subcontracted drug manufacturing services. It has development and commercialization agreement with Hyfe Inc. for digital therapeutics (DTx) for chronic cough. The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.